muraglitazar (Pargluva)
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
- may be more likely than thiazolidinediones to cause edema & heart failure
- increased mortality, risk of myocardial infarction, stroke (composite risk statisically significant)[3]
Mechanism of action
- glitazar, a so-called 2 in 1 drug
- improves blood glucose similar to thiazolidinediones
- improves lipid profile similar to fibrates
- lowers triglycerides almost 30%
- raises HDL almost 20%
- activates both PPAR-alpha & PPAR-gamma
- activation of PPAR-gamma decreases plasma glucose & free fatty acid concentrations
- activation of PPAR-alpha receptors decreases plasma triglyceride & increases plasma HDL cholesterol
More general terms
References
- ↑ Prescriber's Letter 12(9): 2005 Diabetes Drugs on the Horizon: Investigational Drug: Muraglitazar (Pargluva) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210905&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Internal Medicine News 38(16) August 2005
- ↑ Jump up to: 3.0 3.1 Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005 Oct 20; [Epub ahead of print]; JAMA 294(20):2581, 2005 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16239637
Brophy JM, Selling safety - Lessons from muraglitazar JAMA 294:2633, 2005 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16239638